DOCSLIB.ORG

Commercial Model of the Future

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Commercial Model of the Future BioPharma BD Quarterly Newsletter Q2 2018 Syneos Health Consulting Commercial Strategy & Planning | Portfolio Strategy Solution Center Syneos Health BioPharma BD Quarterly Newsletter | Q2 2018 Q2 FDA Approvals | Q3 PDUFA Dates | Q2 Deal Summary | Q2 Mergers & Acquisitions | Q2 Partnerships | Q2 Asset Purchases Q2 FDA Approvals1,2 In order of 2020 sales forecast No sales listed Aimovig (erenumab) | Novartis / Amgen (co- Akynzeo IV (fosnetupitant) | Helsinn Group commercialize) . Prevention of acute and delayed nausea Migraine, first CGRP receptor blocker associated with cancer chemotherapy . 2020E Sales: $470M Bendamustine HCl Injection (bendamustine AndexXa (andexanet alfa) | Portola hydrochloride) | Spectrum Pharmaceuticals / Pharmaceuticals Eagle Pharmaceuticals (co-promotion Neel Patel . Used for uncontrolled bleeding in patients that agreement) used rivaroxaban and apixaban . Chronic lymphocytic leukemia Managing Director . 2020E Sales: $258M [email protected] Consensi (amlodipine besylate) | Kitov / Dexcel Fulphila (pegfilgrastim) | Mylan / Biocon Pharma Technology (cooperation agreement- (partnership) Dexcel will develop drugs final formulation-Kitov . Decrease incidence of infection, as manifested by pays Dexcel $3.5M for company’s facilities) febrile neutropenia . Amlodipine for hypertension and celecoxib for . 2020E Sales: $244M osteoarthritis Lokelma (sodium zirconium cyclosilicate) | Crysvita (burosumab) | Ultragenyx AstraZeneca / Incyte (clinical trial collaboration) Pharmaceutical . Treatment of hyperkalemia in adults . X-linked hypophosphatemia . 2020E Sales: $225M EB178 (mirabegron) | Astellas Pharma Olumiant (baricitinib) | Eli Lily . Overactive bladder . Severe active rheumatoid arthritis . 2020E Sales: $214M Lucemyra (lofexidine hydrochloride) | Salix Nelson Azoulay Pharmaceuticals / US WorldMeds (co-partner) Director Crysvita (burosumab) | Kyowa Hakko Kirin . Opioid addiction . X-linked hypophosphatemia [email protected] . 2020E Sales: $195M 2 Q2 FDA Approvals1,2, continued In order of 2020 sales forecast No sales listed Doptelet (avatrombopag maleate) | Dova Plenvu (ascorbic acid) | Valeant Pharma / Norgine Pharmaceuticals (licensing agreement-Valeant to develop and . Thrombocytopenia in patients with chronic liver commercialize) disease . Cleansing of the colon in preparation for . 2020E Sales: $180M colonoscopy Imvexxy (17-beta estradiol) | TherapeuticsMD Yonsa (abiraterone acetate) | Sun Pharmaceutical . Moderate to severe dyspareunia Industries / Churchill Pharmaceuticals (Sun Katya Magonova . 2020E Sales: $131M launches Yonsa due to licensing deal with Engagement Manager Churchill) Palynziq (phenylalanine ammonia lyase) | . Metastatic castration resistant prostate cancer [email protected] BioMarin Pharmaceutical . Treatment of phenylketonuria . 2020E Sales: $125M Tavalisse (fostamatinib disodium) | Rigel Pharmaceuticals . Treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia . 2020E Sales: $93M Retacrit (epoetin alfa) | Vifor Pharma Group / Fresenius / NovaQuest / Pfizer (commercialization agreement for certain channels) . Anemia due to chronic kidney disease and Jeff Tan zidovudine in patients with HIV-infection Analyst . 2020E Sales: $49M [email protected] 3 Q2 Deal Summary Q2 2018 No. of Deals No. of Deals Tot. Deal Value Avg. Deal No. of Deals** Avg. Upfront Summary total with disclosed Value With upfront Payments finances payments Mergers & 24 15* $19.90B $1.32B 5 $1.33B Acquisitions Partnerships 108 24 $8.50B $0.35B 10 $0.04B Asset Purchases & 14 6 $5.57B $0.93B 3 $0.87B Other *One deal was removed due to rejection in merger † **Comprised of only deals with disclosed finances Total Value of Deals by Therapeutic Area $14.0B $12.3B $11.7B $12.0B $10.0B $8.0B $6.0B $5.5B $5.4B $3.7B $4.0B Total Value of Deals ($B) $2.0B $0.0B Cancer Neurology Other Diagnostics Autoimmune M&A Partnerships Asset Purchases †Total value of deals is comprised of only deals with disclose finances. Deals that are indicated for multiple therapeutic areas have been double counted and those that are not indicated for a therapeutic area have been excluded 4 Q2 Deal Summary | Top Mergers & Acquisitions (by $) Tot. Deal Upfront Buyer Seller Deal Type Novartis was the largest spender in Q2 Value Payment with an upfront payment being the total deal value of $8.7B4 Novartis AG AveXis Inc. Full Acquisition $8.70B $8.70B • After the announcement of AveXis Inc. deal with Novartis’s board, Novartis AG Roche Foundation Medicine Inc. Full Acquisition $2.40B $2.40B acquired a potentially first-ever one-time Zoetis Inc. Abaxis Inc. Full Acquisition $2.00B $2.00B gene replacement therapy for spinal muscular atrophy, AVXS-101 Eli Lily & Co. Armo BioSciences Inc. Full Acquisition $1.60B - • AVXS-101 shows life-saving efficacy with all infants event free at 20 months Johnson & BeneVir Biopharm Inc. Full Acquisition $1.04B $0.14B • AVXS-101 is expected to be on the market Johnson by 2019, with an estimated multi-billion dollar peak sale Companies Deal Type Tot. Deal Value • Both companies supported the acquisition as it would allow Novartis AG to become Keryx Biopharmaceuticals Inc. and Akebia Therapeutics Merger $1.30B the leader in neurodegenerative diseases Inc. to merge to become Akebia Therapeutics Inc. Q2 Deal Summary | Top Partnerships (by $) Tot. Deal Upfront Licensee Licensor Asset Pfizer and Allogene Therapeutics entered Value Payment into an asset contribution agreement for Pfizer’s allogeneic CAR T immuno- Allogene 5 Pfizer Inc. Pharmaceutical Products $2.80B - oncology portfolio Therapeutics Inc • Pfizer participates financially to continue Axovant the development of allogeneic CAR T Oxford BioMedica plc Pharmaceutical Products $0.84B $0.03B Sciences Ltd. therapy through 25% ownership stake in Shionogi & Co. Sage Therapeutics Allogene Pharmaceutical Products $0.57B $0.09B Ltd. Inc. • The two companies will continue to develop CAR T both for children with acute Vifor Pharma Cara Therapeutics lymphoblastic leukemia and for adults with Ltd. / Fresenius Pharmaceutical Products $0.54B $0.05B Inc. advanced lymphomas SE & Co. KGaA Oxford Biomedica and Axovant Sciences Daiichi Sankyo Zymeworks Inc. Discovery Technology $0.48B $0.02B entered into a $800M exclusive worldwide Co. Ltd. license agreement6 Sigilon Therapeutics • Axovant Sciences is going to help develop Eli Lilly and Co. Pharmaceutical Products $0.47B $0.06B Inc. and commercialize AXO-Lenti-PD, a gene CStone therapy treatment for Parkinson’s disease Agios Pharmaceuticals Pharmaceutical Products $0.42B $0.01B • Axovant will gain 7% - 10% tiered royalties Pharmaceuticals Inc. Co. Ltd. on the net sales of AZO-Lenti-PD 5 Q2 Deal Summary | Top Asset Purchases (by $) Assets (by $) Buyer Seller Asset Phase Tot. Deal Value Upfront Payment Shire's cancer business, including Servier Shire Plc acute lymphoblastic leukemia (ALL) Marketed $2.40B $2.40B drug, Oncaspar pegaspargase Advent International Zentiva Group A/S European generics Sanofi Not Applicable $2.30B $2.30B Corp. business Spark Therapeutics a rare pediatric disease Priority Jazz Pharmaceuticals plc Not Applicable $0.11B $0.11B Inc. Review voucher Guangzhou Industrial Investment Fund Takeda Management Co. Ltd. / 51% stake in JV Guangdong Pharmaceutical Co. Not Applicable $0.28B $0.28B Shanghai Techpool Bio-Pharma Ltd. Pharmaceuticals Holding Co. Ltd. Biogen Inc. TMS Co. Ltd. TMS-007 and backup compounds Phase II $0.36B $0.04B Advent International entered into exclusive negotiations leading to the acquisition of Zentiva, Sanofi’s European generics business7 • Advent will work collaboratively with Sanofi to form a new independent operation, supporting the Zentiva management team to invest in the company’s operations and production facilities and R&D pipeline Shire Plc, a leading global biotechnology company focused on rare diseases, entered into an agreement to sell its Oncology business to Servier8 • Shire’s Oncology business includes in-market ONCASPAR, a component of multi-agent treatment for acute lymphoblastic leukemia, and their rights to ONIVYDE, a component of multi-agent treatment for metastatic pancreatic cancer patients whose disease progressed after a gemcitabine-based therapy • Shire’s portfolio also includes Calaspargase Pegol which is under FDA review for the treatment of acute lymphoblastic leukemia in a multi-agent chemotherapeutic regimen. • Shire’s oncology business had sales of $262 million last year, putting the divestment on a respectable revenue multiple of 9.2 times Royalties (by $) Buyer Seller Asset Phase Tot. Deal Value Upfront Payment HealthCare Royalty La Jolla Giapreza angiotensin II Marketed $0.13B $0.13B Partners Pharmaceutical Co. 6 Q3 FDA PDUFA Dates3, 7, 8 Drug Name Indication Date PDUFA Review RISPERIDONE (RBP-7000) Schizophrenia Approved: 28-Jul Priority AZEDRA (Iobenguane) Pheochromocytoma Approved: 30-Jul Priority ORILISSA (Elagolix) Endometriosis Approved: 31-Jul Priority KALYDECO (Ivacaftor) Cystic fibrosis Approved: 07-Aug Omadacycline Acute bacterial skin infection Approved: 08-Aug Priority Familial amyloidotic polyneuropathy in patients with PATISIRAN Approved: 11-Aug Priority ATTR EYLEA (Aflibercept) Wet AMD Approved: 11-Aug GALAFOLD (Migalastat) Fabry disease Approved: 13-Aug Priority ORKAMBI (Lumacaftor / Ivacaftor) Cystic fibrosis 15-Aug OPDIVO (Nivolumab) Small cell lung cancer 16-Aug Priority Stannsoporfin Jaundice 22-Aug Priority PRALUENT (Alirocumab) For use with apheresis 24-Aug Post-operative
Load more

Recommended publications
  • Product Brand List November, 2015
    Product Brand List November, 2015 BD™ BD Autoguard-N Pro™ BD CARV II™ BD 6CESS™ BD Autoguard™ BD Cato™ 6mm™ (circle design) BD AutoMagic™ BD CatoPAN™ BD A-Cath™ BD AutoNutrient™ BD Chemocato™ BD Accu-Glass™ BD AutoPap™ BD CDT™ BD Accuri™ BD AutoSceptor™ BD Cefinase™ BD Accuspray™ BD AutoShield™ BD CellFIT™ (EU only) BD Acidicase™ BD AutoShield Duo™ BD CellFIX™ (EU only) BD Activ 8™ BD Ayre Cervi-Scraper™ BD Cellmatics™ BD Activation Assist™ BD BACTEC™ BD CellQuest™ Pro BD ACTOne™ BD BACTEC FX™ BD CellWASH™ (EU only) BD Adams™ BD BACTEC™ MGIT™ BD CFlow™ BD Adsyte™ BACTEC Plus Prime™ (Japan) BD Champion™ BD Affirm™ BD Bacto™ BD Chek™ BD AICE™ BD Bact-Plate™ BD CHG™ BD A-Line™ BD Bactrol™ BD CLIC™ BD Amplatz™ BD Bactrol™ Plus BD CLyse™ BD Angiocath Plus/Pro™ (Asia only) BD BaculoGold™ BD CS Quadcount™ BD Angiocath-N™ Autoguard™ BD Barricor™ BD CSampler™ BD Angiocath™ BD BBLCrystal™ BD CX Sampler™ BD Angiocath™ Autoguard™ BD BBL™ CHROMagar (under license) BD Angio-set™ BD BBL™ Crystal™ BD Clay Adams™ BD Apem™ BD BeAware™ BD Cliniject™ BD Asepta-Cell™ BD Bio-Bag™ BD CloneCyt™ BD Asepto™ BD Biosate™ BD CloneCyt™ Plus BD Assurity Linc™ BD BiTek™ BD CMVscan™ BD Attofluor™ BD Bonnano™ BD ColorPAC™ BD Atto™ BD Busher™ BD Connecta™ BD Attovision™ BD Calibrite™ BD Cornwall™ BD Attractors™ BD Calibrite™ 3 BD CPT™ BD Autocrit™ BD CampyPak™ BD CrystalSpec™ BD Autocyte™ BD CampyPak™ Plus BD Crystal™ BD Autocyte Quic™ BD CampyPouch™ BD Autoguard Pro™ BD Campyslide™ Product Brand List November, 2015 cont'd BD CSI™ BD Easy™ BD FACSLyric™ BD CTA Medium™
    [Show full text]
  • Becton Dickinson 2000 Annual Report
    Becton, Dickinson and Company 2000 Annual Report Tools for human health 2000 Annual Report Becton, Dickinson and Company 1 Becton Drive Franklin Lakes, NJ 07417-1880 http://www.bd.com Becton, Dickinson and Company Corporate Information Board of Directors Contents Harry N. Beaty, M.D.1,4 Albert J. Costello1,6 Frank A. Olson2,5,6 James E. Perrella2,3,5 1 Letter to Shareholders Emeritus Dean–Northwestern Retired Chairman of the Board, Chairman of the Board Retired Chairman of the Board– 5 Tools for Human Health University Medical School, and President and Chief Executive and Retired Chief Executive Ingersoll-Rand Company 16 At a Glance Chairman of the Board and Officer–W.R. Grace & Co. Officer– The Hertz Corporation Alfred Sommer1,3 President–Northwestern Gerald M. Edelman, James F. Orr1,4 Dean of the Johns Hopkins 18 Nine-Year Summary University Medical Faculty M.D., Ph.D.4,5,6 Chairman, President and School of Hygiene and Public 20 Financial Review Foundation Director–The Neurosciences Chief Executive Officer– Health, and Professor of 28 Financial Statements Henry P. Becton, Jr.2,3,4 Institute, Member–The Scripps Convergys Corporation Ophthalmology, Epidemiology 49 Corporate Information: President and General Manager– Research Institute Willard J. Overlock, Jr.2,5,6 and International Health 5 1,4 Board of Directors, WGBH Educational Foundation Edward J. Ludwig Retired Partner–Goldman, Margaretha af Ugglas Clateo Castellini3,5 President and Chief Sachs & Co. Member of the Board– Corporate Officers and From laboratory Chairman of the Board–BD Executive Officer–BD Stockholm University and General Information Jarl Hjalmarson Foundation Committees Appointed by the 1 – Audit Committee to living room, Board of Directors 2 – Compensation and Benefits Committee Corporate Officers Edward J.
    [Show full text]
  • BD Pyxis™ Inventory Connect Brochure
    PIS BD PyxisTM Inventory Connect Safe and efficient inventory management of automated and manual pharmacy stock enabling accurate inventory visibility, compliance and control Medication management faces significant challenges Drug shortages Drug waste 59% 20% of European pharmacists have of hospital inventory is seen care delayed because of discarded2 drug shortages1 Inefficiency Medication errors Over 237 half million of pharmacists’ work time is spent medication errors occur on tasks considered to be in the United Kingdom non-value adding3 each year4 When medication management relies on manual processes, lacks inventory control and involves redundant documentation procedures, it can be time-consuming, inefficient and error-prone3. Some pharmacy information systems (PIS) may have limitations in the way they handle medication inventory in non-automated storage locations adding to these inefficiencies and loss of time. Controlled and efficient inventory management The BD solution for safe, compliant, accurate and integrated inventory management is BD Pyxis™ Inventory Connect. BD Rowa™ Connected and scalable across locations BD Pyxis™ FMD Verify BD Pyxis™ Guided Pick Integrated FMD compliance Improved picking and storing efficiency Actionable analytics - enhanced order management It provides controlled and efficient inventory management, visibility and reporting in both automated and manual stock locations and will integrate to fill the existing gaps of today’s pharmacy information systems. PIS NMVS PIS BD Pyxis™ Inventory Connect BD Pyxis™
    [Show full text]
  • BECTON, DICKINSON and COMPANY (Exact Name of Registrant As Specified in Its Charter) New Jersey 22-0760120 (State Or Other Jurisdiction of (I.R.S
    As filed with the Securities and Exchange Commission on November 24, 2010 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 2010 COMMISSION FILE NUMBER 1-4802 BECTON, DICKINSON AND COMPANY (Exact name of registrant as specified in its charter) New Jersey 22-0760120 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 1 Becton Drive 07417-1880 Franklin Lakes, New Jersey (Zip code) (Address of principal executive offices) (201) 847-6800 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Name of Each Exchange on Which Registered Common Stock, par value $1.00 New York Stock Exchange Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¥ No n Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes n No ¥ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • BD Sterifill Advance™ Brochure
    BD Sterifill AdvanceTM Make it a part of your drug launch strategy Polymer Pre-fillable Syringe for Intravenous Drugs Integrate the BD Sterifill Advance™ Polymer Pre-fillable Syringe into your drug launch or Life Cycle Management strategy Do you know, approximately 92% of hospital Differentiate stakeholders* in a study were willing to use pre-filled your drug-prefilled device syringes for multiple drugs?1 In fact, transitioning a fixed dose combination with drug from its vial or ampule format to a prefilled syringe (PFS) BD Sterifill Advance™ can serve as a differentiation strategy in a market dominated by features and benefits: 2,3 vials and ampules. • Cyclo Olefin Polymer • Screw-on tip cap that is preferred Keep your First-to-Market advantage on track by healthcare professionals over conventional push-on rubber tip cap4** • BD Sterifill Advance™ supports your “First-Mover” strategy with usability data from human factors and reports on • Time associated with drug preparation compatibility with syringe pumps.8†† can be reduced in comparison to conventional, immediate use syringes • This data can help you streamline your drug filing process and vials/ampules5† and address relevant questions from regulatory bodies on combination product usability.†† • Available in sizes 5, 10, 20 and 50 ml • BD Sterifill Advance™ polymer pre-fillable syringe has been • Compatibility demonstrated 6‡ validated for intravenous manual infusions for 5,10, and 20ml with different syringe pumps and syringe pump based infusions for 20 and 50ml in human factors studies.6‡,7§ Footnotes: * Stakeholder respondents include risk managers & infection control nurses, intensive care nurses, business/ department managers, pharmacists, and anesthesiologists according to a quantitative survey (n=147) on “Drivers of use of prefilled syringes” conducted in UK, France and Germany.
    [Show full text]
  • Becton, Dickinson and Company / CR Bard, Inc., in the Matter Of
    ANALYSIS OF AGREEMENT CONTAINING CONSENT ORDERS TO AID PUBLIC COMMENT In the Matter of Becton, Dickinson and Company and C. R. Bard File No. 171 0140, Docket No. C-4637 I. INTRODUCTION The Federal Trade Commission (“Commission”) has accepted, subject to final approval, an Agreement Containing Consent Orders (“Consent Agreement”) from Becton, Dickinson and Company (“BD”) and C. R. Bard, Inc. (“Bard”) (collectively, the “Respondents”) that is designed to remedy the anticompetitive effects that would likely result from BD’s proposed acquisition of Bard. The proposed Decision and Order (“Order”) requires the Respondents to divest all rights and assets related to Bard’s tunneled home drainage catheter business and BD’s soft tissue core needle biopsy device business to Merit Medical Systems, Inc. (“Merit”). The Order To Maintain Assets requires Respondents to maintain the viability and competitiveness of the businesses pending divestiture. Pursuant to an Agreement and Plan of Merger, dated as of April 23, 2017, BD and Lambda Corp., a wholly-owned subsidiary of BD, will acquire the issued and outstanding shares of Bard by means of a merger in exchange for cash and stock valued at approximately $24 billion (the “Acquisition”). The Commission’s Complaint alleges that the proposed Acquisition, if consummated, would violate Section 7 of the Clayton Act, as amended, 15 U.S.C. § 18, and Section 5 of the Federal Trade Commission Act, as amended, 15 U.S.C. § 45, by substantially lessening competition in the U.S. markets for tunneled home drainage catheter systems and soft tissue core needle biopsy devices. The Consent Agreement is designed to remedy the alleged violations by preserving the competition that otherwise would be lost in these markets as a result of the proposed Acquisition.
    [Show full text]
  • Contact: Kate Babb/Stephanie Hughes
    1 Becton Drive Franklin Lakes, NJ 07417 www.bd.com News Release Contact: Monique N. Dolecki, Investor Relations – 201-847-5453 Colleen T. White, Corporate Communications – 201-847-5369 BD ANNOUNCES RESULTS FOR 2011 SECOND FISCAL QUARTER Franklin Lakes, NJ (April 26, 2011) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $1.922 billion for the second fiscal quarter ended March 31, 2011, representing an increase of 6.8 percent from the prior- year period. On a foreign currency-neutral basis, revenue increased 4.6 percent, despite an unfavorable comparison to the prior year of about 2.3 percentage points due to strong sales related to the H1N1 flu pandemic, supplemental spending in Japan and stimulus spending in the U.S. in fiscal year 2010. “We are pleased with our solid results this quarter, which were in line with our expectations,” said Edward J. Ludwig, Chairman and Chief Executive Officer. “We continued the increased pace of our R&D spending and made strategic investments, such as our acquisition of Accuri Cytometers, demonstrating our commitment to driving revenue growth through innovation.” Update on Impact of Japan Earthquake and Tsunami Order volumes for BD products in Japan have now returned to normal levels. The Company’s manufacturing plant in Fukushima sustained some earthquake-related damage, but the prepared plated media manufacturing lines were recently restarted, and manufacturing of BD HypakTM Prefillable Syringes is expected to resume during the third fiscal quarter 2011. BD’s Fukushima distribution center and an additional distribution center near Tokyo are in operation.
    [Show full text]
  • Life Sciences Supplier Guide
    º º º º º º º º Inspiring Innovation º º º º º º º º Life Sciences Supplier Guide Abnova™ • Axygen PCR Plastics • Fisherbrand Cryovials • Cell Lysates • Axygen Photodocumentation System • Fisherbrand Electroporation Cuvets • ELISA Kits • Axygen Robotic Tips • Fisherbrand Erlenmeyer Style • In Situ Hybridization • Cell Counters and Accessories Shaker Flasks • Monoclonal and Polyclonal Antibodies • Cell Culture Consumables • Fisherbrand Microscope Slides • Recombinant Proteins • Cell Culture Inserts • Fisherbrand PCR Consumables Analytik Jena • Classical and Serum-Free Media • Isotemp™ CO2 Incubators • Photodocumentation Systems • Cryogenics Products • Microplate Heater • Transilluminators • Fetal Bovine Serum • Microscopes • UV Equipment • Matrigel™ and Other • Mini Electrophoresis Systems Applied Biosystems™ Cell Culture Matrices • Washers • PCR, RT-PCR Reagents • Single-Use Technologies GE HealthcareTM • qPCR Reagents • Spheroid Plates • Amersham™ Membranes • qPCR Instruments • Stem Cell Culture Media • Autoradiography Film • TaqMan® qPCR Assays and Probes • Thermal Cyclers • Centrifugation Media • Thermal Cyclers Decon • Chromatography Columns and Media • Capillary Electrophoresis • Detergents • Electrophoresis • SeqStudio™ Genetic Analyzer • Disinfectants • Cell Culture Media • BigDye™ Reagents Digilab, Inc. • HyClone • ExoSAP-IT™ Kits • Hydroshear • Fetal Bovine Serum and Other BD Biosciences* • Hydroshear Plus Serum Products • Antibodies Eppendorf North America • Cell Culture Reagents • Cytometric Bead Arrays • Centrifuges • Nucleic
    [Show full text]
  • Helping All People Live Healthy Lives B E C T O N , D 2007 Annual Report I C K I N S O N a N D C O M P a N Y 2 0 0 7 a N N U a L R E P O R T
    10% Cert no. SGS-COC-3028 Helping all people live healthy lives 2007 Annual Report Becton, Dickinson and Company 2007 Annual Report trademarks of Becton, Dickinson and Company. ©2007 BD. trademarks of Becton, Dickinson and Company. e .bd.com Becton Drive BD and BD Logo ar 1 Franklin Lakes, NJ 07417 www Corporate Officers Edward J. Ludwig John R. Considine David W. Highet Chairman, President and Senior Executive Vice President and Vice President and Chief Intellectual BD, a leading global medical technology company that Chief Executive Officer Chief Financial Officer Property Counsel Richard K. Berman Helen Cunniff William A. Kozy manufactures and sells medical devices, instrument systems Vice President and Treasurer President – Asia-Pacific Executive Vice President Donna M. Boles Jean-Marc Dageville Dean J. Paranicas Senior Vice President – Human Resources President – Western Europe Vice President, Corporate Secretary and and reagents, is dedicated to improving people’s health Public Policy Mark H. Borofsky David T. Durack, M.D. Vice President – Taxes Senior Vice President – Corporate Carmelo Sanz de Barros throughout the world. BD is focused on improving drug Medical Affairs President – Latin America James R. Brown Vice President – Quality Management Vincent A. Forlenza Jeffrey S. Sherman therapy, enhancing the quality and speed of diagnosing Executive Vice President Senior Vice President and General Counsel Scott P. Bruder, M.D., Ph.D. Senior Vice President and A. John Hanson Patricia B. Shrader infectious diseases, and advancing research and discovery of Chief Technology Officer Executive Vice President Senior Vice President, Corporate Regulatory and External Affairs Gary M. Cohen Laureen Higgins new drugs and vaccines.
    [Show full text]
  • Solutions for High-Dimensional Flow Cytometry Deep Exploration Tools from BD Biosciences
    Solutions for high-dimensional flow cytometry Deep exploration tools from BD Biosciences BD presents the high-parameter solution Figure 1: BD FACSymphonyTM flow cytometer Figure 2: BD HorizonTM Brilliant dyes (Brilliant Figure 3: FlowJoTM version 10.5 advanced data Violet, Brilliant Ultraviolet and Brilliant Blue) analysis software We support you with everything, from experimental design to analysis, to allow you to push your science to the limits. High-dimensional flow cytometry Bring state-of-the-art technology into your science More colours Optimising existing panels Allow a better understanding of the complex functions of With high-dimensional flow cytometry, existing panels can the immune system. be optimised with better dyes to minimise compensation and data spreading. This will improve resolution and provide clearer information on receptor expression Broad lineage panels patterns. Allow better insights into the cellular composition of organs or peripheral blood in a single tube for applications Our new broad phenotyping panel where the target population is not known before the experiment. A large number of cell lineages in peripheral blood can now be screened with our new broad phenotyping panel. Deep phenotyping panels Allow the analysis of multiple expression patterns on a defined cell subset to learn more about the biology of immune functions Read on to discover the potential of the BD FACSymphonyTM and its associated new dyes. List of monoclonal antibodies and dyes for the 27-colour broad phenotyping panel Antibody Clone Label
    [Show full text]
  • In Memoriam Henry P. Becton, Sr
    Volume 29 Number 2 December 2009 In Memoriam Henry P. Becton, Sr. Inside This Issue It is with deep sadness that we report the passing of BD’s Director Emeritus Henry P. Becton, Sr. Becton died on October 25th at his BD Prepares for home in Blue Hill, Maine at the age 2009 H1N1 Flu of 95. Known as “Hank” by his colleagues and friends, he devoted his entire professional life to BD, the company founded by his father, Maxwell W. Becton, and Col. Fairleigh S. Dickinson, Sr. “Hank was the living embodiment of BD’s purpose and values. His glowing smile was the very face of BD,” said Ed Ludwig, BD Chairman Henry P. Becton, Sr. and Chief Executive Officer. “It was an honor to know Hank personally and to be mentored by him as I grew in the Company.” Becton left an indelible mark on BD, serving as Executive Vice President, Chairman of the Executive Committee of the Board of Directors and Chairman of the Board in the years of the Company’s BD greatest growth and expansion. He saw BD grow from 600 associates Box 059, 1 Becton Drive and sales of $2.5 million to 29,000 associates and over $7 billion in Franklin Lakes, NJ 07417-1880 annual sales. Editor Becton and Fairleigh S. “Dick” Dickinson, Jr. shepherded BD Alice Moskowitz through the “disposables revolution” and into the production of Telephone: 973.942.3086 [email protected] single-use sterile products. They also guided the Company as it made the transition from a family business to a professionally managed, Advisory Committee publicly owned corporation listed on the New York Stock Exchange.
    [Show full text]
  • BD Biosciences Product Catalog
    BD Biosciences Product Catalog 2 TABLE OF CONTENTS GENERAL INFORMATION 9 BD PHARMINGEN RAT 181 (TRANSDUCTION LABORATORIES) BD Biosciences Company Profile 10 BRAND PRODUCTS 115 Antibodies to Rat Leukocytes and Related Cells 182 Facilities 11 Antibodies to Rat Major Histocompatibility 188 Systems Products 117 Complex (MHC) Antigens How To Order 12 Cytometric Bead Array (CBA) 118 Antibodies to Rat T-Cell Receptors (TCR) 189 Technical Services 18 DimerX MHC:Ig Recombinant Fusion Proteins 120 Product Warranties 21 ELISPOT Instrumentation and Reagents 122 NON-HUMAN PRIMATE 191 Trademarks, Patents, and Abbreviations 24 IMag Magnetic Particles 126 Antibodies for Non-Human Primate Research 192 BD BIOSCIENCES CUSTOM Monolight 3096 Microplate Luminometer 128 Mouse Immunoglobulin Isotype Controls 195 PRODUCTS AND SERVICES 29 BD PowerBlot Western Array Screening Service 130 Rat Immunoglobulin Isotype Controls 195 BD IMMUNOCYTOMETRY RESEARCH REAGENTS 133 SYSTEMS BRAND PRODUCTS 39 OTHER NON-HUMAN SPECIES 197 IMMUNOHISTOCHEMISTRY 133 Systems Products 41 Antibodies to Dog Leukocytes 198 Instruments and Data Management 57 Antibodies to Guinea Pig Leukocytes 198 Kits 134 Sample Preparation and Instrument Setup 79 Antibodies to Pig Leukocytes 198 Detection Systems and Substrates 135 Service and Customer Education 83 Antibodies to Rabbit Leukocytes 199 Multiple Tissue Arrays (MTA) 136 Buffers and Fixatives 137 CLINICAL & RESEARCH REAGENTS 93 HUMAN 201 Antibodies for Human IHC 138 Tumor Markers/Cell Biology 140 System Reagents 94 Antibodies to Human Leukocytes
    [Show full text]